AIM's Serum-Free Iterative Rabies Vaccine Receives Acceptance for Market Registration; Institutions Predict Significant Valuation Recovery Potential for the Company

, /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, announced on April 7, 2025 that the company's research and development of the serum-free iterative rabies vaccine has received an "Acceptance Notice" from the National Medical Products Administration for market registration. In addition, the vaccine has obtained the corresponding product production license. Currently, there are no serum-free rabies vaccines approved for sale in the global market, and this product is expected to become the first of its kind to launch.

AIM Vaccine is rapidly advancing the market launch process for its iterative major vaccine products, confirming the optimistic forecasts made by investors. As noted in a research report published by Fosun International Securities on April 3, the operational improvements at AIM Vaccine have been validated, its innovative pipeline is ready to launch, and there is significant potential for valuation recovery. With the upcoming launches of three major new products, including the serum-free iterative rabies vaccine in the next 1-2 years, the company's revenue is expected to accelerate, and profitability is projected to improve significantly, potentially achieving breakeven and quickly entering a profit period after 2025. The target price for the company is maintained at HKD 11.22, with a "Buy" rating.

According to the research report from Fosun International Securities, AIM's serum-free rabies vaccine well represents the direction of technological upgrades in rabies vaccines. The production process does not use animal serum, significantly increasing safety and reducing allergy risks, with excellent efficacy and safety indicators shown in Phase III clinical trial results.

The serum-free iterative rabies vaccine is recognized as a high-value product in the industry. The report from Fosun International Securities points out that, based on solidifying its market share in Vero cell vaccines, AIM's serum-free iterative rabies vaccine and its iterative high-yield diploid cell (HDC) vaccine represent significant technological upgrades and value enhancement capabilities. The HDC vaccine is priced significantly higher than the current Vero cell vaccine, which still holds 95% of the market share, while the serum-free vaccine, with its higher safety profile, is expected to further surpass the pricing of the HDC vaccine.

PRC is the largest rabies vaccine market globally. According to statistics from Frost & Sullivan, driven by product upgrades and increasing rabies vaccine awareness, it is expected to reach RMB 14.8 billion by 2030. According to the "National Regulation for the Rabies Exposure Prophylaxis (2023 Edition)" established by the National Disease Control and Prevention Administration (NDCPA) and the National Health Commission of PRC(NHC), rabies vaccination clinics are required to provide at least two different types of rabies vaccines. AIM's serum-free rabies vaccine, with its technological advantages, is expected to become the first choice for vaccination institutions.

As such, the report from Fosun International Securities believes that AIM has not only maintained its strong market share acquisition and commercialization capabilities in the mature vaccine market but has also made crucial progress in its transition to high-value vaccines.

With the gradual realization of its product line, AIM is expected to continuously improve cash flow and achieve profitability after 2025. With its rich product pipeline, leading technology platform, and forward-looking strategic layout, AIM Vaccine is set to play an increasingly important role in both the PRC and global vaccine markets.